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ABSTRACT
Background and the purpose of the study: MEN1 is an important tumor suppressor gene that 
encodes a nuclear protein called menin. Recent data suggest that interactions between menin 
and other proteins have important roles in control of the cell cycle and apoptosis. In addition, 
estrogen receptor (ER), an important prognostic factor is differentially expressed in breast cancer 
cells. In this study the MEN1 gene and protein expression in MCF7, T47D and MDA-MB-468 
breast cancer cell lines with different ER status following exposure to adriamycin (ADR) was 
investigated. 
Materials and methods: Cytotoxicity of ADR on these cell lines was determined using MTT 
assay. The mRNA and protein levels were analyzed in tested cell lines using RT-PCR and 
immunocytochemistry (ICC) assays, respectively. 
Results: ADR cytotoxicity was highest on MDA-MB-468 and lowest on MCF7 cells. MEN1 
mRNA showed significant decrease after ADR exposure only in the MDA-MB-468 cell line. 
Menin protein expression was higher in MDA-MB-468 and lower in MCF7 cells. 
Conclusion: Differential molecular responses to adriamycin were observed in cancer cell lines. 
Molecular data also suggest that MEN1 as a new biomarker can be used in combination with 
current biomarkers for prediction of response to chemotherapy.
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INTRODUCTION
Breast cancer, one of the most common malignancies 
affecting  women  today  (1),  is  associated  with 
different types of genetic alterations such as mutations 
in  oncogenes  and  tumor  suppressor  genes.  MEN1, 
classified as a gate keeper tumor suppressor gene is 
responsible for multiple endocrine neoplasia type1 
(2) and is widely observed in non-endocrine as well 
as endocrine and exocrine tissues (3, 4). Menin, the 
protein product of the MEN1 gene is a 67-kDa nuclear 
protein (5). The nuclear localization of menin suggests 
that it may have functions such as telomerase activity, 
transcriptional regulation, DNA replication or cell cycle 
control  (6,  7).  These  important  functions  of  menin 
may make it potentially a good candidate biomarker to 
predict the responses of cancer cells to chemotherapy.
Menin  interacts  with  a  diverse  group  of  transcription 
factors  and  chromatin  modifying  proteins  including 
Jun,  Smad3,  mSin3A,  histone  deacetylases  and 
vitamin  D  (8-10).  These  reports  suggest  a  role  for 
menin in the regulation of gene expression at the 
level  of  transcription  and  chromatin  modification 
(11). Menin has also been shown to interact with 
FancD2, a protein that participates in DNA repair, as 
well as RPA2, a protein required for DNA replication, 
recombination and repair (12, 13). Menin also directly 
binds to DNA which is important for its function in 
regulating cell proliferation (14). Furthermore, it has 
been reported that complementation of menin-null 
cells with menin increases the activation of caspase 
8 in response to TNF-α treatment, suggesting a role 
in promoting apoptosis as another critical function 
of menin (15). It is well-known that most of the 
chemotherapeutic drugs induce DNA damage that 
leads to cell death via apoptosis. Therefore, it can 
be crucial to elaborate relationship of the interaction 
of menin expression in different cancer cells and 
anticancer  activity  of  drugs.  On  the  other  hand, 
menin  is  a  transcriptional  co-activator  of  the 
nuclear receptors for estrogen and vitamin D and can 
directly interact with the estrogen receptor (ER) in 
a  hormone  dependent  manner  (10,  16).  Estrogen 
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corresponding flasks. The medium was changed 
every 48 hrs with corresponding assay medium. 
After 48 hrs total RNA was isolated using TriPure 
isolation reagent (Roche, Germany) according to 
the previously described method (19). 
RT-PCR
The  cDNA  from  each  sample  was  synthesized 
and subjected to polymerase chain reaction (PCR) 
according to the previously described method (19). 
To  amplify  sequence  of  MEN1,  specific  primers 
were designed by Perl Primer software followed by 
BLAST (sense,5´-GCT GGC TGT ACC TGA AAG 
GA  -3´;  antisense,5´-CTT  GTG  GTA  GAG  GGT 
GAG TG -3´). As an internal control, the β-actin 
specific primers were also designed by Perl Primer 
software followed by BLAST (sense,5´-TGA CGG 
GGT  CAC  CCA  CAC  TGT-3´;  antisense,5´-CTA 
GAA  GCA  TTT  GCG  GTG  GAC-3´).  The  PCR 
setting for MEN1 and β-actin was 30 cycles at 95°C 
for 30s, 57°C for 30s and 72°C for 30s. The PCR 
products  were  visualized  using  1.2%  agarose  gel 
electrophoresis and staining with ethidium bromide. 
In negative control template was replaced by DEPC 
water. Experiment was repeated in 3 separate time 
and results were visualized and photographed using 
Bio  Doc  It  (UVP  Co,  USA)  to  be  analyzed  for 
densitometry by Lab Works 4.5 software.
Immunocytochemical  analysis  of  menin  expression
The cells (MCF7, T47D and MDA-MB-468) were 
seeded in 8-well chamber slides (Lab Teck, USA) 
in  RPMI  1640  culture  medium  and  incubated 
in  a  humidified  CO2  incubator  (5%  CO2, 37°C). 
After  48  hrs  culture  medium  was  changed  and 
adriamycin  [MCF7  (500  nM),  T47D  &  MDA-
MB 468 (250 nM)] was added for 48 hrs to wells 
of  each  chamber  slide  while  the  medium  of  the 
control wells remained RPMI 1640. The cells were 
then subjected to immunocytochemical analysis as 
previously described (20) to determine the menin 
expression using menin primary antibody (Abcam, 
USA).  Finally  immunostained  cells  were  studied 
under light microscope and photographed. A section 
in which incubation with the primary antibody was 
omitted used as negative control. 
Statistical analyses
All  cellular  and  molecular  experiments  were 
repeated 2-3 times after optimization and data were 
presented as mean ± SE of independent experiments 
that were analyzed using one way ANOVA followed 
by dunnett post test. Mean differences with P<0.05 
were considered statistically significant.
RESULTS
Cytotoxic  effects  of  different  concentrations  of 
Adriamycin  on  MCF7,  T47D  and  MDA-MB-468 
and  its  receptor  (ER)  play  important  roles  in  the 
genesis and malignant progression of breast cancer. 
ERα regulates the transcription of various genes as 
a transcription factor. It binds to estrogen response 
elements (ERE) upstream of the target genes (17). 
Differential expression of ER in breast cancer cells 
is  an  important  biomarker  in  cancer  therapy  and 
hence, it is interesting to know the possible role of 
ER and menin in responses of different breast cancer 
cells to chemotherapy. 
Therefore,  the  aim  of  the  present  study  was  to 
investigate the expression pattern of MEN1 tumor 
suppressor gene and menin protein as a biomarker 
in MDA-MB-468, T47D and MCF7 breast cancer 
cell  lines  with  different  ER  status  to  predict  the 
response to drugs such as adriamycin, a well-known 
chemotherapeutic drug.
MATERIAL  AND  METHODS
Cell lines and culture conditions
The human breast cancer cell lines (MCF7, T47D 
and MDA-MB-468) were obtained from National 
Cell Bank of IRAN (Pasteur Institute). Cells were 
maintained in RPMI 1640 culture medium (Gibco, 
UK)  supplemented  with  10%  fetal  bovine  serum 
(Gibco, UK) and 100 U ml-1 of penicillin and 100 
ng ml-1 of streptomycin at 37°C in 5% humidified   
CO2  incubator.
Determination  of  cytotoxicity  of  different  con-
centrations or concen-trations of adriamycin on MCF7, 
T47D and MDA-MB-468 breast cancer cell lines
The cells were seeded in 96-well plates at 1x104 
cells/well  in  RPMI  1640  culture  medium  and 
incubated at 37°C in 5% CO2 incubator for 48 hrs. 
The cells were then exposed to adriamycin (EBEWE 
Pharma,  Austria)  at  different  concentrations  (100 
nM, 250 nM, 500 nM and 1000 nM) for 48 hrs. The 
medium was changed every 48 hrs with corresponding 
assay  medium  and  the  anti-proliferative  effect  of 
adriamycin was evaluated using MTT assay (18).
Determination  of  the  time  dependency  anti-
proliferative activity of adriamycin on MCF7, T47D 
and MDA-MB-468 breast cancer cells
For this purpose cells were exposed to culture medium 
containing 500 nM of drug for MCF7 and 250 nM 
for T47D and MDA-MB-468 cell lines. Then MTT 
method (18) was daily used to determine the growth 
curve of each cell line within 5 days of drug exposure.
RNA isolation 
The cells (MCF7, T47D and MDA-MB-468) were 
seeded  in  T-25  flasks  in  RPMI  1640  culture 
medium and incubated in a humidified CO2 incubator 
(5% CO2, 37oC). After 48 hrs culture medium was 
changed and adriamycin [MCF7 (500nM), T47D 
&  MDA-MB-468  (250nM)]  was  added  to  the MEN1 expression in breast cancer cells 19
breast cancer cell lines
Different  patterns  of  cytotoxicity  of  adriamycin 
(ADR) exposure for 48 hrs were observed in tested 
cell lines using MTT assay. ADR showed significant 
dose-dependent anti-proliferative effect on MCF7, 
T47D and MDA-MB-468 cells (Fig. 1).
Time-course cytotoxic effects of adriamycin on MCF7, 
T47D and MDA-MB-468 breast cancer cell lines
Adriamycin showed time-dependent anti-proliferative 
effects on MCF7, T47D and MDA-MB-468 cells 
(Fig. 2). The cytotoxicity was highest on MDA-MB-
468 cells after 5 days exposure to 250 nM of ADR 
than T47D cells in MTT assay. The MCF7 cells 
was less sensitive to cytotoxic effects of ADR at all 
time-points in comparison to other two cell lines. 
Effect of adriamycin on the mRNA level of MEN1
RT-PCR  analyses  of  MEN1  mRNA  expression 
showed  slight  decrease  in  MDA-MB-468  and 
MCF7 cell lines after exposure to ADR (Fig. 3). The 
expression of MEN1 mRNA was highest in MDA-
MB-468 and lowest in MCF7 cell line in comparison 
with  untreated  samples  (Fig.  3).  MEN1  mRNA 
expression  was  significantly  reduced  after  ADR 
treatment only in MDA-MB-468 cells.
Immunostaining  of  breast  cancer  cell  lines  with 
menin antibody
Menin  expression  showed  an  increase  after ADR 
exposure in all cell lines which qualitatively was 
higher  in  MDA-MB-468  and T47D  and  lower  in 
MCF7 cell lines in comparison to immunostaining 
pattern of RPMI control under the light microscope 
(Fig.4).
DISCUSSION
ADR is a topoisomerase IIα poison. Topoisomerase 
IIα  is  a  nuclear  enzyme  that  transiently  breaks 
 
RESULTS 
Cytotoxic  effects  of  different  concentrations  of  Adriamycin  on  MCF7,  T47D  and 
MDA-MB-468 breast cancer cell lines: 
Different  patterns  of  cytotoxicity  of  adriamycin  (ADR)  exposure  for  48  hrs  were 
observed  in  tested  cell  lines  using  MTT  assay.  ADR  showed  significant  dose-
dependent anti-proliferative effect on MCF7, T47D and MDA-MB-468 cells (Fig. 1). 
0
10
20
30
40
50
60
70
80
90
100
0 200 400 600 800 1000 1200
Concentration (nM)
O
D
 
5
4
0
 
p
e
r
c
e
n
t
 
t
o
 
c
o
n
t
r
o
l
 
(
R
P
M
I
)
MDA-MB 468
T47D
MCF7
 
Fig. 1) Cytotoxic effects of different concentrations of Adriamycin on breast cancer cell lines. 
Cells were seeded in 96-well plates and exposed for 48h to adriamycin to determine its cytotoxicity 
using MTT method. Data are mean ± SE of the average of 4 wells in three independent experiments. 
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Figure 2.  Time-course cytotoxic effects of adriamycin on breast 
cancer cell lines. Cells were seeded in 96-well plates and exposed 
for 5 days to adriamycin to determine its cytotoxicity using MTT 
method. Data are mean ± SE of the average of 4 wells in three 
independent experiments for MCF7 (A), T47D (B), and MDA-
MB-468 (C) cell lines.
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A) Effect of Adriamycin (500 nM) on MCF7 cell line
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B) Effect of Adriamycin (250 nM) on T47D Cell Line
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A) Effect of Adriamycin (500 nM) on MCF7 cell line
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C) Effect of Adriamycin (250 nM) on MDA-MB 468 Cell Line
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Fig. 2)  Time-course cytotoxic effects of Adriamycin on breast cancer cell lines. Cells were seeded 
in  96-well  plates  and  exposed  for  5  days  to  adriamycin  to  determine  its  cytotoxicity  using  MTT 
method. Data are mean ± SE of the average of 4 wells in three independent experiments for MCF7 (A), 
T47D (B), and MDA-MB-468 (C) cell lines. 
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Fig. 3) Effect of Adriamycin on the mRNA levels of MEN1 in T47D, MDA-MB-468 and MCF7 
cell lines. Expression level of MEN1 mRNA was detyermined using RT-PCR that repeated 3 times 
after optimization (A). Densitometric analysis of 3 separate experiments using Lab Works 4.5 software 
is shown as mean ±SE of relative intensity of each band normalized to  ȕ-Actin (B). ** indicates 
significant difference compared to RPMI with p<0.001.   
 
Immunostaining of breast cancer cell lines with menin antibody: Menin expression 
showed  an  increase  after  ADR  exposure  in  all  cell  lines  which  qualitatively  was 
higher in MDA-MB-468 and T47D and lower in MCF7 cell lines in comparison to 
immunostaining pattern of RPMI control under the light microscope (Fig.4). 
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Fig. 4) Immunostaining of MCF7, T47D and MDA-MB-468 cells with menin antibody. ADR 
treated MCF7 (A), T47D (C) and MDA-MB-468 (E) and untreated MCF7 (B), T47D (D) and MDA-
MB-468 (F) cells showed different pattern and intensity of menin expression visualized by labvision 
detection system using AEC chromogen. (Magnification 400x)   
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transiently breaks and rejoins the phosphodiester backbone of both strands of the 
double helix. Therefore, it is essential for DNA replication, chromosome segregation, 
and maintenance of chromosome structure. ADR forms a stable complex with DNA 
and topoisomerase IIĮ resulting in inhibition of the normal function of the enzyme. 
The complexed enzyme is unable to religate DNA and as a result DNA strand breaks 
and DNA damage would be increased (21). 
In this study, the MEN1 mRNA and protein expressions were analyzed in different 
breast  cancer  cells  following  exposure  to  ADR.  MEN1  mRNA  level  decreased 
significantly after ADR treatment only in MDA-MB-468 that is ER negative but not 
in ER positive MCF7 and T47D cell lines. The difference between MEN1 mRNA 
level in MCF7 that is lower than T47D cells could be due to other genetic differences 
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Figure 4. Immunostaining of MCF7, T47D and MDA-MB-468 
cells with menin antibody. ADR treated MCF7 (A), T47D (C) 
and MDA-MB-468 (E) and untreated MCF7 (B), T47D (D) and 
MDA-MB-468 (F) cells showed different pattern and intensity of 
menin expression visualized by labvision detection system using 
AEC chromogen. (Magnification 400x) 
and re-joins the phosphodiester backbone of both 
strands of the double helix. Therefore, it is essential 
for DNA replication, chromosome segregation, and 
maintenance of chromosome structure. ADR forms 
a stable complex with DNA and topoisomerase IIα 
resulting in inhibition of the normal function of the 
enzyme. The complexed enzyme is unable to religate 
DNA and as a result DNA strand breaks and DNA 
damage would be increased (21).
In  this  study,  the  MEN1  mRNA  and  protein 
expressions were analyzed in different breast cancer 
cells  following  exposure  to ADR.  MEN1  mRNA 
level  decreased  significantly  after ADR  treatment 
only in MDA-MB-468 that is ER negative but not 
in  ER  positive  MCF7  and  T47D  cell  lines.  The 
difference between MEN1 mRNA level in MCF7 
that is lower than T47D cells could be due to other 
genetic differences between these two cell lines such 
as lower ER and higher progesterone receptor (PR) 
expression  and  also  mutation  in  p53  gene  in  the 
T47D cells in comparison to the MCF7 cells. The 
molecular differences between cell lines under study 
further emphasizes on inverse relationship between 
MEN1 and expression level of ER.
It  has  been  already  reported  that  menin  has 
multifunctions  such  as  transcriptional  regulation, 
repression  of  cell  proliferation,  and  promotion 
of  apoptosis  (22). Analysis  of  DNA  synthesis  in 
cultured cells also revealed that overexpression of 
menin inhibited DNA synthesis (23). In this study, 
menin expression in all cell lines increased relatively 
after exposure to ADR. Similarly, gamma irradiation 
has been reported to increase menin in the nuclear 
matrix (11). Similarly, it has also been shown that 
menin  responds  to  UV  induced  DNA  damage  by 
localizing to the chromatin (23). Therefore, increased 
in  menin  expression  in  MDA-MB-468,  MCF7 
and T47D cell lines after exposure to ADR could 
be explained by its role in repairing DNA damage 
caused by adriamycin and induction of apoptosis. 
Interestingly, MEN1 mRNA expression showed to 
be highest in ER-negative MDA-MB-468 cells and 
lowest  in  the  highly  ER-positive  MCF7  cell  line 
indicating an inverse relationship between MEN1 
and ER expression in these cell lines.
ER  mRNA  was  re-expressed  in  cancer  cells  in  a 
time and dose dependent manner, with up to five 
fold increase in ER expression. However, the ER 
CpG island remained methylated with ER mRNA 
levels induced to only 1 to 10% of those which were 
observed in MCF7 and T47D ER+ cell lines (24). It 
has been reported that menin interacts with ER and 
increases the activity of ER in breast cancer that 
is important as a predictive factor in resistance to 
hormone therapy with tamoxifen (25).
Another possible mechanism underlying the inverse 
relationship between MEN1 and ER expression in 
breast cancer cells could be recruitment of HDAC 
by  menin  which  is  associated  with  decrease  in MEN1 expression in breast cancer cells 21
acetylation of histones H3 and H4, and thus reduction 
of ER expression (26).
Studying  the  expression  of  MEN1,  a  putative 
tumor suppressor gene, is important as a biomarker 
to predict the drug response of cancer cells at both 
mRNA and protein levels following exposure to 
adriamycin,  a  well  known  anticancer  drug. The 
expression pattern of MEN1, especially at protein 
level  after  treatment  with  ADR  is  consistent 
with  its  role  in  the  induction  and  regulation  of 
apoptosis. 
In  this  study,  the  expression  of  MEN1  gene  was 
analyzed  for  the  first  time  in  breast  cancer  cell 
lines  and  it  was  found  that  MEN1  is  expressed 
differentially in breast cancer cell lines with different 
ER status and a negative correlation between MEN1 
and ER expression was observed. 
Finding of this investigation suggest that the clinical 
spectrum of multiple endocrine neoplasia type 1 also 
might include breast cancer, although more studies 
are required to elucidate the exact role of the MEN1 
gene in this disease. In addition, these data suggest 
the requirement for considering new biomarkers that 
can be used in combination with current ones for 
early diagnose of disease and prediction of response 
to chemotherapy.
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